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ABSTRACT
Background: Measuring total kidney volume (mTKV) in autosomal dominant polycystic 
kidney disease (ADPKD) by magnetic resonance image (MRI) and manual tracing is time 
consuming. Two alternative MRI methods have recently been proposed to estimate TKV 
(eTKVELLIPSOID and eTKVPANK) which require less time.
Methods: ADPKD patients with a wide range of kidney function and an approved T2 
weighted MRI performed at the University Medical Centers of Groningen, Leiden, Ni-
jmegen and Rotterdam, the Netherlands from 2007 to 2014. Test-set for assessing re-
producibility n=10, cohort for cross-sectional analyses n=220, and cohort for longitudinal 
analyses n=48. Performances of the gold standard method of manual tracing kidney vol-
umes were compared to both estimation methods.
Results: In the test-set, intra- and inter-coefficients of variation for mTKV, eTKVELLIPSOID 
and eTKVPANK were 1.8 and 2.3%, 3.9 and 6.3%, and 3.0 and 3.4%, respectively. In cross-sec-
tional analysis, baseline mTKV, eTKVELLIPSOID and eTKVPANK were 1.96 (1.28-2.82), 1.93 (1.25-
2.82) and 1.81 (1.17-2.62) liters, respectively. In cross-sectional analysis, Bias was 0.02±3.2, 
1.4±9.2 and 4.6±7.6% for repeat mTKV, eTKVELLIPSOID and eTKVPANK, respectively.  In longitu-
dinal analysis, no significant differences were observed between % change in measured 
TKV (16.7±17.1%) and % change in eTKVELLIPSOID (19.3±16.1%) and eTKVPANK (17.8±16.1%) over 
three years.
Conclusions: Both methods for eTKV perform relatively well compared to mTKV, and can 
detect change in TKV over time.  Since eTKVELLIPSOID  requires less time than eTKVPANK, we 
suggest this method may be preferable in clinical care.
186
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INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the forma-
tion and growth of numerous cysts in both kidneys, leading to an increase in kidney vol-
ume. These cysts compress healthy kidney tissue, causing progressive kidney function 
decline, and in most patients ultimately a need for renal replacement therapy. In ADPKD 
patients, total kidney volume (TKV) has shown to be an early marker of disease severity 
and predictor of kidney function decline1. Measurement of TKV is therefore used to as-
sess prognosis in clinical care and for selection of patients for randomized controlled tri-
als2. In these trials that investigate potential treatments for ADPKD patients assessment 
of TKV is often used as primary or secondary study endpoint3-5.
The true gold standard method to assess TKV is the manual tracing method. Computer 
Tomogram or Magnetic Resonance Images (MRI) is used, in which per slice the kidney 
boundaries are traced manually using dedicated software. mTKV is calculated from a set 
of contiguous images by summing the products of the area measurements within the 
kidney boundaries and slice thickness6. This method is laborious, which limits its use in 
trial settings, but especially in clinical care.
In case kidney volume could be estimated with sufficient accuracy and reliability, it 
would alleviate the time consuming process of kidney volume measurement. Recently, 
two kidney volume estimation methods have been developed: the mid-slice method 
by the CRISP consortium7 and the ellipsoid method by the Mayo Clinic2. For both meth-
ods, measured and estimated kidney volumes appeared to be well correlated, but other 
groups have yet not validated these methods. In addition, the mid-slice method was de-
veloped in a cohort that included only patients with a creatinine clearance >70 ml/min. 
Such patients have in general relatively small kidneys making manual tracing measure-
ment of TKV relatively easy, which may have influenced the results that were obtained. 
This method should therefore also be validated in patients with lower kidney function. 
Estimation methods to assess TKV may also be used in clinical trials, but only when they 
can accurately and reliably detect changes in TKV over time. To our knowledge these is-
sues have not been investigated yet.
Given these considerations, the objective of the present study was to investigate cross-
sectionally the aforementioned methods to estimate TKV in a patient group with a wide 
range of kidney function. Furthermore, we investigated in a longitudinal study whether 
these estimation methods can accurately detect changes in TKV.
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METHODS AND MATERIALS
Patients and study design
For this study, all MRIs of ADPKD patients that were available from 2007 to 2014 were 
used. These patients participated in one of three studies that were performed by the 
departments of Nephrology at the University Medical Centers (UMCs) of Groningen, Lei-
den, Nijmegen and Rotterdam (all in The Netherlands). Details of the study protocols 
have been published elsewhere; see the Supplementary flow diagram describing the as-
sembly of the cohort4,8,9. All patients were included if an MRI-image was available. Sub-
jects were diagnosed with ADPKD based on the modified Ravine criteria10. The Medical 
Ethical Committee of the UMC Groningen approved the protocols of the three studies 
that were conducted in accordance with the International Conference of Harmonization 
Good Clinical Practice Guidelines and in adherence to the ethical principles that have 
their origin in the Declaration of Helsinki. All patients gave written informed consent.
Measurement and collections
All participants collected a 24-hour urine sample the day preceding the MRI-scan, in 
which urinary albumin concentration was measured. At the outpatient clinic on the day 
of the MRI, blood pressure was assessed at rest in a supine position with an automatic 
device (Dinamap; GE Medical Systems) for 15 minutes and weight and height were deter-
mined. Blood samples were drawn for determination of creatinine with an enzymatic as-
say (isotope-dilution mass spectrometry traceable; Modular, Roche Diagnostics), which 
was used to estimate glomerular filtration rate was using the CKD-EPI equation (eGFRCKD-
EPI)11,12.
Magnetic resonance imaging
All participants underwent a standardised abdominal MRI-protocol without the use of 
intravenous contrast. For the specific MRI-protocol, see the Supplementary Methods.
Gold standard method; measured total kidney volume (mTKV)
Kidney and liver volumes were measured preferably on the coronal fat saturated T2-
single shot fast spin echo sequence. If the T2-weighted images showed too low quality, 
the MRI was excluded. The kidney and liver volumes were measured using the manually 
tracing method. The kidney and liver boundaries were manually traced using the com-
mercially available software Analyze Direct 11.0 (Analyze Direct, Inc., Overland Park, KS, 
USA). The kidney and liver volumes were calculated from the set of contiguous images by 
summing the products of the area measurements within the kidney or liver boundaries 
188
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and slice thickness6. Non-renal parenchyma e.g. the renal hilus, was excluded from 
measurement.
Estimation methods; estimated TKV (eTKV)
The two formulas used to estimate kidney volume were derived from literature2,7. We 
first used the mid-slice method to estimate TKV (eTKVPANK)7. The mid-slices of the coronal 
MR images were selected for each kidney separately. The mid-slice was defined as the 
slice of which the slice number corresponds to the half of the sum of the numbers of 
the first and the last slice that contained the kidney. If the sum was odd, the mid-slice 
number was rounded up. eTKVPANK was calculated in mL, with mid-slice area and slice 
thickness in mm2 and mm, respectively. eTKVPANK was calculated as the sum of the left 
eKVPANK and right eKVPANK, with left eKVPANK = 0.624 * mid-slice area * number of slices 
covering the left kidney * slice thickness/1000, and right eKVPANK) = 0.637 *  mid-slice area 
* number of slices covering the right kidney * slice thickness/1000. Second, we used the 
ellipsoid method to estimate TKV (eTKVELLIPSOID)2. Per kidney, length was measured as 
the  average maximal longitudinal diameter measured in the coronal and sagittal plane. 
Width was obtained from the transversal image at maximum transversal diameter, and 
depth was measured from the same image perpendicular to the width measurement. eT-
KVELLIPSOID was calculated in mL, with length, width and depth in mm, respectively. eTKVEL-
LIPSOID was calculated as the sum of the left KVELLIPSOID and right KVELLIPSOID, both derived by 
the equation π/6 * (lengthcoronal + lengthsagittal)/2 * width * depth/1000. Of note, to 
assess eTKVELLIPSOID no specific software is necessary, in contrast to assessment of mTKV 
and eTKVPANK.
Statistical analyses
All analyses were performed with SPSS, version 22.0 (SPSS Inc). Normality of data was 
assessed by drawing Q-Q plots. Normal distributed variables are expressed as mean ± 
standard deviation (SD), whereas non-normal distributed variables are given as median 
with interquartile range (IQR). Baseline characteristics of the study population are given 
overall (Table 1) and stratified for eGFR < and ≥ 60 mL/min/1.73m2 (Supplementary Table 
1).
Differences between groups were tested using a two-sample t test for normal distrib-
uted and a Mann-Whitney U test for non-normal distributed data. For paired analyses, a 
paired t test was used for normal distributed and a Wilcoxon-signed rank test for non-
normal distributed data. McNemar test was used for paired nominal data. A two-sided 
p<0.05 was considered to indicate statistical significance.
189
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In a test-set of ten patients, stratified for kidney volume and MRI-scanner, kidney vol-
umes were measured and estimated twice by four reviewers. All reviewers were blinded 
for their previous results. Reproducibility was evaluated by assessing intra- and inter-
coefficient of variation (CV) for mTKV, eTKVELLIPSOID and eTKVPANK. The inter-CV was calcu-
lated for each of the 10 MRIs as the SD of TKV values assessed by all 4 assessors divided 
by the mean TKV of that MRI multiplied by 100%. The inter-CV given in the manuscript is 
the mean of the inter-CVs of these 10 MRIs. The intra-CV was calculated per MRI for each 
of the 4 assessors as the SD of TKV values divided by the mean TKV multiplied by 100%. 
Per assessor an average intra-CV was calculated. The intra-CV given in the manuscript is 
the mean intra-CV (plus SD) of these 4 assessors. We used a paired t test to compare CV’s 
between measured and estimated TKV. This information has also been added.
To investigate whether eTKV correlated with mTKV, orthogonal regression analysis was 
performed, and Lins’ concordance correlation coefficient (CCC) was calculated using all 
MRI-scans of our cohort13. Orthogonal regression uses the least square data modeling 
technique in which observational errors in both dependent and independent variables 
are taken into account. Agreement between eTKV and mTKV was evaluated by Bland-
Altman analyses, with calculation of agreement limits (95% Confidence Interval [CI]). We 
used manual tracing as gold-standard for total kidney volume measurement on the x-
axis. Performance of the estimation methods compared with mTKV was assessed us-
ing bias, precision and accuracy. For cross-sectional analyses, bias is expressed as mean 
percentage difference (mTKV - eTKV) / mTKV*100%), with positive values indicating an 
underestimation of mTKV. Precision was defined as 1 standard deviation of bias. Accu-
racy was calculated as the percentage of eTKV values within 10%, 15% and 20% of mTKV 
(P10, P15, and P20 respectively). To investigate whether bias is dependent on patient or MRI 
characteristics, we performed regression analyses between bias and various variables 
i.e. age, length, BMI, liver volume and T1/T2 weighted images in univariate analyses. Dif-
ferences in bias among the various scanners that were used, were tested with analysis 
of variance (ANOVA). As standard quality control ~10% of all MRI-scans were measured 
twice for mTKV, and named this mTKVREPEAT. This was done to ensure that the observers 
maintained low inter-observer variability. These scans were used to assess precision and 
bias of mTKV.
To investigate whether the estimation methods can accurately detect changes in TKV, 
data of patients who had follow-up MRIs available were used. For these longitudinal 
analyses bias is expressed as (%change in mTKV - %change in eTKV). Importantly, all 
follow-up scans were performed at the same MRI-scanner as at baseline, and TKV was
190
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measured and estimated using the same images series as at baseline, by reviewers blind-
ed for the baseline results.
To assess the consequences of using eTKV instead of mTKV, two analyses were per-
formed. First, the effect on classification based on disease prognosis was assessed. To 
assess prognosis for clinical care, a classification system is used that categorizes patients 
into five classes based on thresholds for height corrected TKV (HtTKV) at a given age 
(A through E, with A indicating the best and E the worst prognosis with respect to fu-
ture kidney function decline)2. In addition, there is a classification indicating whether a 
patient is suitable for inclusion in clinical trials. This classification contains three classes: 
patients that should not be included in clinical trials [I], patients whose suitability should 
be re-evaluated at yearly intervals [II] and patients that are optimal candidates for clini-
cal trials [III])2. To assess reclassification, we created 5x5 and 3x3 cross-tabulations us-
ing HtTKV limits for their specific age2. In these tables the proportion of reclassified 
participants were calculated when using HteTKV instead of HtmTKV. For this analysis 
only the “typical cases” were used, as advised for this classification system, defined as 
MRIs with cysts with bilateral and diffuse distribution, where all cysts contribute simi-
larly to TKV2. Second, we assessed what the consequences were for sample size calcu-
lation for clinical trials using change in eTKV instead of change in mTKV. Sample size 
calculations were based on literature14 and used data of all patients who had longitudi-
nal follow-up data available with respect to change in mTKV and eTKV. The number of 
patients needed per group was calculated assuming a power of 80% and a two-sided α 
of 0.05 to detect a percentage difference in TKV growth between treatment groups15.
RESULTS
Study participants
The study population consisted of 220 patients with ADPKD. We excluded 44 patient, be-
cause no T2-weighted images were available to perform both estimation methods. Their 
characteristics are listed in Table 1. These patients were relatively young with a mean age 
of 47.0±8.6 years and showed already clear signs of disease. Most patients used anti-
hypertensive medication. Their eGFR was impaired (56.8±20.3 mL/min*1.73m2), with a 
wide range in eGFR (from 17.0 to 129.2 mL/min*1.73m2). Urinary albumin excretion (46.7 
[21.2-88.2] mg/24h) and total kidney volume (1.96 [1.28-2.82] L) were increased.
191
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Table 1. Participants’ characteristics.
Reproducibility of mTKV and eTKV
Table 2 shows a test-set for assessing reproducibility The average intra-observer CV was 
1.8% for mTKV and 2.6% for total liver volume, whereas the inter-observer CV was 2.3% 
and 3.5%, respectively. The variability for eTKVELLIPSOID was significantly higher than for 
mTKV, whereas for eTKVPANK no significant differences were found when compared to 
mTKV. Analysis time was approximately 55 minutes per MRI for mTKV and 65 minutes for 
total liver volume, with higher analysis times in case of larger organs. The average time 
needed per MRI to estimate TKV using the mid-slice method was 15 minutes and using 
the ellipsoid method 5 minutes.
Performance of the TKV estimation methods
In the cohort for cross-sectional analyses, the correlations of mTKV vs. mTKVREPEAT, eT-
KVELLIPSOID and eTKVPANK are shown in Figure 1.
Supplementary Figures 1 and 2 shows these correlations for left and right kidneys 
separately. High correlations were observed for all three methods: mTKVREPEAT r=0.998 
(p<0.001), eTKVELLIPSOID r=0.989 (p<0.001), and eTKVPANK r=0.990 (p<0.001). Figure 1 also 
shows Bland-Altman plots of mTKV vs. the percentage difference between mTKV and 





N 220 48 10
Age (y) 47.0 ± 8.6 39.2 ± 7.4 44.3 ± 10.2
Male (% (n)) 51.8 (114) 70.8 (34) 30 (3)
Body mass index (kg/m2) 26.9 ± 4.3 26.3 ± 3.4 27.1 ± 7.2
Body surface area (m2) 2.0 ± 0.2 2.1 ± 0.2 1.96 ± 0.2
Diastolic blood pressure (mm Hg) 82.2  ± 9.5 82.6 ± 8.8 85.4 ± 11.0
Systolic blood pressure (mm Hg) 132.7 ± 13.0 132.9 ± 11.6 134.1 ± 18.0
Antihypertensive medication (% (n)) 86.4 (190) 81.3 (39) 90 (9)
Plasma creatinine (mmol/L) 125.5 ± 39.7 102.1 ± 31.7 127.4 ± 20.4
eGFR (mL/min/1.73m2) 56.8 ± 20.3 79.7 ± 22.6 49.6 ± 10.2
24h Urine volume (L) 2.36 ± 0.77 2.48 ± 0.87 2.60 ± 0.80
Albuminuria (mg/24h) 46.7 (21.2 – 88.2) 46.2 (19.0 – 181.0) 67.9 (17.0 – 95.4)
Total kidney volume (L) 1.96 (1.28 – 2.82) 1.79 (1.36 – 2.56) 1.78 (1.37 – 2.86)
- Left kidney volume (L) 1.00 (0.67 – 1.52) 0.99 (0.73 – 1.39) 0.92 (0.70 – 1.62)
- Right kidney volume (L) 0.92 (0.60 – 1.38) 0.80 (0.57 – 1.17) 0.91 (0.67 – 1.24)
Liver volume (L) 2.74 (1.73 – 3.07) NA 1.76 (1.62 – 3.64)
192
9
Proefschrift-Binnenwerk-ITI-23042019.indd   188 23/04/2019   12:54 PM
Estimation of total kidney volume in ADPKD 
Figure 1. Cohort for cross-sectional analyses: Associations between measured total kidney 
volume (mTKV) and repeated mTKV (mTKVREPEAT) (upper panels), estimated TKV using the 
ellipsoid method (eTKVELLIPSOID) (middle pannels) and the mid-slice method (eTKVPANK) (lower 
panels). Left panel shows scatter plots (solid line representing the line of identity and the 
dotted line the actual regression line), whereas the right panel shows Bland-Altman plots 
(solid line indicating no difference and dotted lines representing mean difference [i.e. bias] 
with 95% confidence interval).
193
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Table 2. Test-set for assessing reproducibility. Intra- and inter-observer coefficient of varia-
tion (CV) for measured total kidney volume (mTKV) and for estimated total kidney volume 
using the ellipsoid method (eTKVELLIPSOID) and the mid-slice method (eTKVPANK). All CV were 
calculated based on 10 patients.
*p-value <0.05 for difference in intra- or inter-observer CV eTKV vs. corresponding value of mTKV.
mTKVREPEAT and both eTKV methods. mTKVREPEAT showed low bias (mean 0.02%±3.2%). 
eTKV also did not systematically over- or underestimate mTKV (bias of 1.4%±9.2% and 
4.6%±7.6% for eTKVELLIPSOID and eTKVPANK, respectively, Table 3). Bias for eTKVPANK was  sig-
nificantly higher than for mTKVREPEAT (p=0.005), whereas bias for eTKVELLIPSOID did not sig-
nificantly differ from mTKVREPEAT (p=0.4). Given the lower SD, mTKVREPEAT had a better pre-
cision and therefore better performance when compared to eTKVELLIPSOID and eTKVPANK.
In addition, when these analyses were repeated with ADPKD patients stratified for eGFR, 
we observed no significant difference in bias for eTKVELLIPSOID and mTKVREPEAT  in patients 
with eGFR ≥ 60 mL/min*1.73m2 and eGFR <60 mL/min*1.73m2 (p=0.2 and p=0.3, respec-
tively). Between eTKVPANK and mTKVREPEAT, we observed also no significant difference 
in patients with eGFR < 60 mL/min*1.73m2 (p=0.2) and in patients with eGFR ≥60 mL/
min*1.73m2 (p=0.9) Supplementary Table 2 shows bias, accuracy for eTKV stratified by 
eGFR.
When investigating factors associated with bias, it appeared that liver volume was asso-
ciated with bias in eTKVPANK (p=0.044), but not with eTKVELLIPSOID (p=0.1). Bias was not as-
sociated with age (p=0.5 and p=0.6), height (p=0.8 and p=0.14) and strength of magnetic 
field (p=0.8 and p=0.7), respectively for eTKVELLIPSOID and eTKVPANK.
Ability to detect changes in TKV when using estimation methods
Follow-up data for TKV were available for 48 patients. The baseline characteristics for 
the longitudinal cohort are given in Table 1. 
Left kidney Right kidney Both kidneys
mTKV
- Intra-observer CV (%) 2.3 1.9 1.8
- Inter-observer CV (%) 2.6 2.9 2.3
eTKVELLIPSOID
- Intra-observer CV (%) 4.9* 4.3* 3.9*
- Inter-observer CV (%) 6.0* 8.5* 6.3*
eTKVPANK
- Intra-observer CV (%) 3.8 3.1 3.0
- Inter-observer CV (%) 4.2 3.1 3.4
194
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These patients were younger, showed less signs of disease, with a higher eGFR 
(79.7±22.6 ml/min*1.73m2), but similar urinary albumin excretion (46.2 [19.0-181.0] 
mg/24h). During a follow-up of 3.0 years their mTKV increased from 1.79 (1.36-2.56) 
to 2.18 (1.55-2.73) L (p<0.001). The median difference during follow-up was 0.25 (0.04-
0.54), 0.30 (0.08-0.86) and 0.28 (0.08-0.54) L for mTKV, eTKVELLIPSOID and eTKVPANK, 
respectively (Table 4). Change in eTKV compared to change in mTKV was not signifi-
cantly different for both estimation methods (p=0.2 and p=0.5 for eTKVELLIPSOID and eT-
KVPANK, respectively). Figure 2 plots the percentage change in mTKV vs. the percent-
age change in eTKV. High concordance correlations were observed for eTKVELLIPSOID 
(r=0.798, p<0.001) and eTKVPANK (r=0.866, p<0.001). Percentage change in eTKV did 
not show systematic under- or overestimation, with bias and precision (% change 
mTKV - % change eTKV) -2.2%±10.3% and -1.8%±8.3% for eTKVELLIPSOID and eTKVPANK, respec-
tively (Figure 2). In the majority of the patients, bias for change in eTKV was between 
-10% and 10% (72.3% and 74.5% of patients for eTKVELLIPSOID and eTKVPANK, respectively).
Table 3. Cohort for cross-sectional analyses: Performance of the ellipsoid method and the 
mid-slice method to estimate total kidney volume.
Note: Unless otherwise indicated, values for categorical variables are given as percentages; values for non-
parametric are given as median and interquartile range. P values are calculated by paired t test when nor-
mally distributed, Wilcoxon signed-rank test when non-normally distributed for continues variables and 
McNemar test for nominal variables. Abbreviations and definitions: Bias, mean % difference between mTKV 
and eTKV; Precision, 1 standard deviation of bias; Accuracy, percentage of eTKV values within 10% (P10), 
15% (P15) and 20% (P20) of their corresponding mTKV value; CCC, concordance correlation coefficient. 
* mTKVREPEAT vs. eTKVELLIPSOID   |   % mTKVREPEAT vs. eTKVPANK 
eTKVELLIPSOID eTKVPANK mTKVREPEAT p-value*
Number of patients 220 220 28
Left kidney volume (L) 1.03 (0.65 – 1.48) 0.95 (0.63 – 1.45) 1.03 (0.75 – 1.78) 0.3
- Bias (%) -0.7 5.6 0.1 0.9
- Precision (%) 11.8 9.7 3.6
Right kidney volume (L) 0.90 (0.57 – 1.37) 0.88 (0.54 – 1.33) 0.98 (0.67 – 1.51) 0.003
- Bias (%) 2.0 3.2 0.4 0.048
- Precision (%) 12.4 11.1 3.9
Total kidney volume (L) 1.93 (1.25 – 2.82) 1.81 (1.17 – 2.62) 1.92 (1.51 – 3.18) 0.004
- Bias (%) 1.4 4.6 0.2 0.4
- Precision (%) 9.2 7.6 3.2
- Accuracy
P10 78.1 82.1 100 <0.001
P15 92.7 93.6 100 <0.001
P20 97.7 96.4 100 <0.001
- CCC 0.988 0.987 0.998
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The consequences of using percentage change in eTKV instead of percentage change in 
mTKV as endpoint for sample size calculation for randomized controlled trials were as-
sessed using data of the 48 ADPKD patients of which follow-up data were available. We 
calculated the number of study participants per treatment group needed to be enrolled 
to demonstrate a certain percentage decrease in rate of growth in TKV. The results are 
shown in Supplementary Table 3. 
Figure 2. Cohort for longitudinal analyses: Associations between percentage change in 
measured total kidney volume (mTKV) and percentage change in estimated total kidney 
volume (eTKV) using the ellipsoid method and the mid-slice method in 48 ADPKD patients 
who had follow-up data available. Left panel shows scatter plots (solid line representing the 
line of identity and dotted line the actual regression line), whereas the right panel shows 
Bland-Altman plots (solid horizontal line indicating no difference, and dotted lines repre-
senting mean difference [i.e. bias] with 95% confidence interval).
196
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To detect for instance a 30% decrease in rate of growth in mTKV over a period of 3 years, 
186 patients are needed per treatment group, whereas for eTKVELLIPSOID and eTKVPANK 
these numbers are 122 and 143, respectively.
Table 4. Cohort for longitudinal analyses: Baseline and follow-up total kidney volume (TKV) 
data in 48 ADPKD patients with follow-up data available.
Note: Unless otherwise indicated, values for continuous variables are given as mean standard deviation (if para-
metric) or median [interquartile range] if nonparametric. Abbreviations: mTKV, measured total kidney volume; 
eTKVELLIPSOID, total kidney volume estimated using ellipsoid method; eTKVPANK, total kidney volume estimated us-
ing mid-slice method. Nosignificant differences between change in eTKV vs. change in mTKV were noted, but only 
at change in left eTKVPANK as indicated with an asterisks. * p-value <0.05.
Consequences of using eTKV instead of mTKV
When using the eTKV methods instead of mTKV for risk classification with respect to 
prognosis for rapid kidney function decline, we excluded the radiologically atypical AD-
PKD cases (n=27), as advised for this classification system. 93.3% (eTKVELLIPSOID) and 90.2% 
(eTKVPANK) of the patients were reclassified to their original risk categories (Table 5), 
whereas for both estimation methods, less than 1.6% of the patients were reclassified to 
a higher risk category and less than 8.5% to a lower risk category. For classification for 
selection of patients for clinical trials, we observed that 97.4% (eTKVELLIPSOID) and 95.9% 
(eTKVPANK) of the patients were reclassified to their original categories. No patients were 
reclassified to a higher risk category when using eTKVELLIPSOID and only 1 patient when us-
ing eTKVPANK (Table 5).
Baseline (L) Follow-up (L) Change (L) Change (%)
Left kidney
mTKV 0.99 (0.74 – 1.39) 1.23 (0.83 – 1.56) 0.13 (0.01 – 0.29) 15.0 ± 18.7
eTKVELLIPSOID 1.03 (0.70 – 1.44) 1.26 (0.85 – 1.58) 0.10 (0.04 – 0.37) 17.7 ± 18.1
eTKVPANK 0.92 (0.68 – 1.24) 1.10 (0.78 – 1.44) 0.17 (0.04 – 0.36)* 19.7 ± 19.0*
Right kidney
mTKV 0.80 (0.57 – 1.17) 0.99 (0.68 – 1.29) 0.13 (0.06 – 0.25) 19.4 ± 18.6
eTKVELLIPSOID 0.81 (0.58 – 1.10) 1.04 (0.65 – 1.39) 0.14 (0.04 – 0.29) 23.1 ± 22.8
eTKVPANK 0.78 (0.60 – 1.14) 0.90 (0.65 – 1.24) 0.13 (0.04 – 0.24) 17.0 ± 19.6
Both kidneys
mTKV 1.79 (1.36 – 2.56) 2.18 (1.55 – 2.73) 0.25 (0.04 – 0.54) 16.7 ± 17.1
eTKVELLIPSOID 1.86 (1.32 – 2.75) 2.39 (1.50 – 2.80) 0.30 (0.08 – 0.86) 19.3 ± 16.1
eTKVPANK 1.79 (1.12 – 2.43) 2.03 (1.49 – 2.63) 0.28 (0.08 – 0.54) 17.8 ± 16.1
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Table 5. Reclassification for staging into risk categories for rapid kidney function decline 
for clinical care (A-E) and for selection of patients for clinical trials based on thresholds for 
height corrected TKV at a given age (I-III) using ellipsoid method (eTKVELLIPSOID) and using 
mid-slice method (eTKVPANK) instead of mTKV.
 
DISCUSSION
This study was conducted to investigate whether TKV can be estimated accurately using 
the mid-slice and ellipsoid methods in a group of ADPKD patients with a wide range of 
kidney function. In a test-set of ten ADPKD patients we found that both estimation meth-
ods were highly reproducible. In our study cohort of 220 ADPKD patients both methods 
showed low bias, high precision and high accuracy when compared to measured TKV 
(mTKV). This held for the overall cohort, as well as for patients with higher and lower 
eGFR. In the 48 patients who had follow-up MRIs available, change in estimated TKV 
(eTKV) was not different from change in mTKV for both methods.
Assessment of TKV using the gold standard method is time consuming and needs spe-
cific software, which limits its applicability for clinical care. Methods have therefore been 
sought to estimate TKV in a more feasible way. Two methods have been published re-
cently,2,7 which, however, have yet not been validated. This formed the rationale to per-
form the present study. For determination whether these estimation methods can be 
used to assess TKV, it is of importance to answer the following five questions.
First of all, it is important to investigate what the reliability of the gold-standard method 
is. In our study we found that the variability in volumetric assessment by manual tracing 
(i.e. the gold standard method) was very low. In general, T1-weighted images instead of 
eTKVELLIPSOID eTKVPANK
A B C D E A B C D E
mTKV A 5 A 4 1
B 28 B 1 27
C 5 66 2 C 6 65 2
D 4 47 1 D 6 45
E 1 35 E 3 33
eTKVELLIPSOID eTKVPANK
I II IIII I II IIII
mTKV I 5 I 4             1
II                   28 II 1 27
IIII                                5 155 IIII 6 150
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T2-weighted images are used for volumetry in ADPKD, because researchers want to align 
with the original CRISP methodology. However, when the CRISP study started, gadolini-
um enhanced T1-weighted MR images were used. Because of the potential side effects of 
gadolinium, the use of this contrast agent has since been discouraged. Bae et al showed 
in 2009 that unenhanced T1-weighted volumes were significantly lower than contrast-
enhanced T1-weighted volumes16. These differences were more pronounced in smaller 
kidneys, because in such cases the ratio of kidney boundaries area to kidney volume is 
higher. Bae et al mentioned that one should therefore consider using T2 MR imaging 
for the quantification of TKV, because the high kidney tissue-contrast and hyperintense 
renal cysts in T2 images help delineate the kidney boundaries against the background tis-
sues when compared to T1-weighted images. At that time T2-weighted imaging required 
longer scanning time and was subjected to increased variation in image quality because 
of motion artefacts, and was therefore not feasible. Nowadays T2 weighted scanning 
time is shorter and respiratory-triggered to avoid motion artefacts has become available. 
In our experience this sequence has the best quality in visualising the polycystic kidneys. 
We therefore choose T2-weighted images instead of T1-weighted for our study. 
Second, do these estimation methods show low variability? The variability in mTKV ver-
sus eTKVPANK was not significantly different and satisfactory low. The variability in eTKVEL-
LIPSOID was significantly higher compared to mTKV, meaning that this method is slightly 
more operator-dependent than the mid-slice method, but still low. In line, reclassifica-
tion to another risk category for rapid kidney function decline for clinical care (Irazabal 
classes A-E) happened infrequent when using eTKVPANK, as well as eTKVELLIPSOID (Table 5). 
Given these results, and because eTKVELLIPSOID is more convenient (shorter duration per 
MRI and assessment possible using standard MRI software) we advise to use in clinical 
care eTKVELLIPSOID rather than eTKVPANK for risk assessment.
Third, does the estimation method show good agreement with the gold standard meth-
od? We found for both estimation methods that eTKV correlated strongly with mTKV. 
Although bias and precision showed again better values for mTKVREPEAT (0.02% and 3.2%, 
respectively), the results for eTKVELLIPSOID as well as eTKVPANK for were good. Bias was low 
for eTKVELLIPSOID and eTKVPPANK, (1.4% and 4.6 %, respectively), although for eTKVPANK slight-
ly (but significantly) higher than for mTKVREPEAT. In addition, precision was reasonable, 
now with slightly better results for eTKVELLIPSOID (eTKVELLIPSOID and eTKVPANK 9.2% and 7.6%, 
respectively, Table 3). Consequently we found good accuracy for both estimation meth-
ods (eTKVPANK P20 96.4%, and eTKVELLIPSOID P20 97.7%). Our findings with respect to accu-
racy are consistent with the values obtained in the cohort in which the ellipsoid method 
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was developed (P10 70.3% vs. 78.1% in the present study)2. When stratified for kidney
function our results with respect to bias suggest that the mid-slice method may be less 
accurate in ADPKD patients with lower kidney function, who generally have larger kid-
neys. Besides these statistical data, consequences for clinical care should be investigated 
when answering the question whether estimation methods show good agreement with 
the gold standard method. Irazabal et al proposed a classification system for ADPKD 
patients to assess their risk for rapid kidney function decline and to guide selection of 
patients for clinical trials2. This classification system uses thresholds defined on age and 
height corrected TKV. We investigated the percentage of patients that are reclassified 
when using eTKV instead of mTKV. In the classification system for risk assessment, we 
observed that only a limited percentage of patients was reclassified, and that these pa-
tients were especially reclassified to a lower risk category (Table 5). No fundamental 
differences in results were observed for the two TKV estimation methods, and only one 
patient was reclassified to a risk category that would preclude treatment when using 
eTKVPANK (category B).
Fourth, can the estimation method detect changes in TKV over time? As far as we are 
aware no study has yet investigated the performance of estimation methods to assess 
changes in TKV. In our analyses, we found a high concordance correlation between 
change in mTKV and change in eTKVPANK and eTKVELLIPSOID during three years follow-up, and 
no difference between change in mTKV and change in eTKVPANK and eTKVELLIPSOID (Table 5). 
Consequently, when data are used of change in eTKV instead of change in mTKV, similar 
numbers of patients have to be included in clinical trials to be able to show a decrease in 
rate of growth in TKV (Table 5). These longitudinal results may seem surprising, because 
they appear to be in contrast with our cross-sectional data, where we showed that mTKV 
shows better reliability than eTKVPANK and eTKVELLIPSOID, albeit that these differences were 
small. In our opinion, this may be due to two explanations. It could well be that with 
the eTKV methods a systematic error is made in an individual patient in assessing TKV at 
baseline, for instance due to a peculiar shape of a cystic kidney, but that the same error 
is made during follow-up, because the shape of the cystic kidney has not changed. In this 
way a systematic error in baseline eTKV will not translate in bias in change in eTKV during 
follow-up on a patient level. In addition, the natural variability in growth in TKV between 
patients may be that high, that the limited variability that is added by using eTKV is not 
relevant when assessing mean change in TKV on a group level.
The fifth and last question to be answered is whether the estimation method is feasible 
from a clinical point of view. To estimate TKV using the mid-slice method, special soft-
ware is necessary to measure the mid-slice area, limiting clinical applicability. In contrast, 
all clinicians can estimate TKV by the ellipsoid method using standard MRIs without spe-
cial software. Furthermore, the ellipsoid method requires less time to estimate TKV than 
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using the mid-slice method, and both methods require far less time than assessment of 
mTKV with the gold standard method, i.e. manually tracing method. 
The answers to the above questions indicate that, although eTKV may be slightly less 
precise than mTKV using manual tracing method, it can be used with confidence in clini-
cal care. Because the two eTKV methods show numerically hardly any differences with 
respect to bias, precision and accuracy, and no difference in ability to detect changes in 
eTKV, the more feasible ellipsoid method is to be preferred over the mid-slice method. 
Whether this conclusion is also valid for the use of eTKVELLIPSOID instead of mTKV for clini-
cal trials needs confirmation. To investigate this issue, the results of these two assess-
ment techniques should be compared in large-scale trials between different intervention 
groups using MRIs obtained at baseline as well as during follow-up. Our data form the 
rationale to perform such studies.
A limitation of the present study is that our results hold primarily true for the cross-
sectional correlation between mTKV and eTKV. Our results for follow-up data should be 
interpreted with caution, because the results are based on a limited number of patients. 
Strengths of this study are that we investigated both estimation methods in a group of 
ADPKD patients with relatively well-preserved as well as impaired kidney function, and 
that we are the first to externally validate both estimation methods.
In conclusion, we demonstrated that both methods to estimate TKV perform relatively 
well in ADPKD patients overall, as well as in patients with preserved as well as impaired 
kidney function. In addition, both estimation methods detect relatively accurate chang-
es in TKV over time. Because of these results and the higher feasibility, we advise to use 
the ellipsoid method for TKV estimation in clinical care. Whether this method can also be 
used for clinical trials deserves further study.
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The UMC Groningen used a 1.5-Tesla MR scanner (Magneto Avanto, Siemens, Erlan-
gen, Germany) and a 3-Tesla research MR scanner (Intera, Philips, Eindhoven, the Neth-
erlands). All other centers used a 1.5-Tesla MRI-scan [UMC Leiden: Philips Healthcare, 
Eindhoven, the Netherlands; UMC Rotterdam: GE Medical Systems, Buckinghamshire, 
United Kingdom; and the UMC Nijmegen: Avanto Siemens, Erlangen, Germany]. Coils 
were placed onto the anterior and posterior abdominal walls directly over the kidneys. 
A short scout was scanned to localize the kidneys. Subsequently four series of images 
were scanned. Two T2-fast multislice spoiled gradient echo were scanned coronal and 
transversal, with slice thickness of 4 mm, gap/spacing 0 mm, FOV 35 cm, matrix 256*256, 
TE ≈ 2 ms, TR ≈ 7 ms, Flip Angle 40-50°. Thereafter a T2-single shot fast spin echo was 
scanned coronal (same characteristics, but different TR’s and TE’s per brand MRI-scan-
ner: TE ≈ 100 ms for Siemens, TE ≈ 190 ms and TR ≈ max. 1400 ms for GE and ≈ 70 ms and 
TR ≈ max. 1900 ms for Philips) and a T1-3D spoiled gradient echo coronal (same charac-
teristics except TR ≈ 4 ms and Flip Angle ≤15°). At the beginning and the end of the scan 
sequence had to be at least 1 slice not containing liver and kidney tissue. When a 35 cm 
FOV was insufficient, the FOV could be increased. Preferably, both kidneys as well as the 
liver, including all cysts, had to be covered within one sequence of images. When such 
a sequence could not be scanned, two separate sequences for liver and kidneys were 
allowed. The obtained MR images were anonymized and sent via a secured server to 
the central reading facility at the UMC Groningen, where kidney and liver volume were 
measured. Nine medical students were specifically trained to measure TKV. During their 
training period, they measured 40 kidney volumes and 20 liver volumes under supervi-
sion and guidance of an experienced MRI-technician using a standard operating proce-
dure. After these students completed their training, they were allowed to measure TKV.
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Supplementary Table 1. Baseline characteristics stratified by eGFR
eGFR ml/min/1.73m2
< 60 ≥ 60 p-value
N 145 75
Age (y) 49.5 ± 7.6 42.3 ± 8.5 <0.001
Male (% (n)) 49.0 (71) 57.3 (43) 0.2
Body mass index (kg/m2) 27.0 ± 44.0 26.7 ± 4.8 0.1
Body surface area (m2) 2.04 ± 0.22 2.04 ± 0.22 0.7
Diastolic blood pressure (mm Hg) 82.7 ± 10.0 81.4 ± 8.5 0.2
Systolic blood pressure (mm Hg) 133.8 ± 12.9 130.7 ± 12.9 0.9
Antihypertensive medication (% (n)) 87.6 (127) 78.3 (59) 0.08
Plasma creatinine (mmol/L) 141.8 ± 38.4 93.9 ± 16.2 <0.001
eGFR (mL/min/1.73m2) 45.5 ± 9.0 78.8 ± 17.7 <0.001
24h Urine volume (L) 2.41 ± 0.75 2.28 ± 0.81 0.8
Albuminuria (mg/24h) 53.4 (26.5 - 103.9) 37.8 (16.7 - 87.7) 0.07
Total kidney volume (L) 2.14 (1.42 - 3.14) 1.68 (1.16 - 2.39) 0.02
- Left kidney volume (L) 1.10 (0.72 - 1.73) 0.92 (0.62 - 1.32) 0.1
- Right kidney volume (L) 1.02 (0.66 - 1.51) 0.75 (0.54 - 1.05) 0.004
Liver volume (L) 2.78 (1.71 - 3.20) 2.56 (1.83 - 3.03) 0.5
Unless otherwise indicated, values for categorical variables are given as percentages; values for continuous vari-
ables are given as mean ± standard deviation if parametric or median (interquartile range) if non parametric. 
Abbreviations are: eGFR, estimated glomerular filtration rate (CKD-EPI equation). P-values indicate differences 
between eGFR < 60 and ≥ 60. P-values are calculated by t test when normally distributed and by Mann-Whitney U 
test when non-normally distributed.
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eTKVELLIPSOID eTKVPANK
eGFR ≥60 <60 p-value ≥60 <60 p-value
N 75 145 75 145









- Bias (%) -1.2 -0.5 0.6 4.4 6.2 0.5
- Precision (%) 12.2 11.7 10.7 9.1









- Bias (%) 0.4 2.8 0.9 0.2 4.7 0.5
- Precision (%) 12.2 12.5 9.1 11.8









- Bias (%) 0.7 1.7 0.9 2.7 5.5 0.3
- Precision (%) 8.8 9.3 6.6 7.9
- Accuracy
P10 77.3 78.9 0.8 90.5 77.8 0.02
P15 90.7 93.8 0.4 94.7 93.1 0.6
P20 97.3 100 0.8 97.4 95.9 0.6
- CCC 0.986 0.988 0.989 0.985
P-values are calculated with independent t tests when normally distributed and with Wilcoxon signed-rank tests 
when non-normally distributed for unpaired data, and with paired t tests and McNemar tests for paired data. 
Abbreviations and definitions: eTKVELLIPSOID, estimated total kidney volume using ellipsoid method; eTKVPANK, es-
timated total kidney volume using mid-slice method; eGFR, estimated glomerular filtration rate. Accuracy, per-
centage of estimated total kidney volume values within 10% (P10), 15% (P15) and 20% (P20) of their corresponding 
measured total kidney volume value (TKV). Bias, mean % difference between mTKV and eTKV. Precision, 1 standard 
deviation of bias; CCC, concordance correlation coefficient. P values for eTKVELLIPSOID ≥60 vs. <60 are calculated by 
t test when normally distributed and Mann-Whitney U test when non-normally distributed.
Estimation of total kidney volume in ADPKD 
Supplementary Table 2. Performance of the ellipsoid method and the mid-slice method to 
estimate total kidney volume (eTKVELLIPSOID and eTKVPANK, respectively), stratified for eGFR 
≥60 en <60 ml/min/1.73m2.
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Supplementary Table 3. Number of participants per treatment group needed for rand-
omized controlled trials to be able to show a specific % difference in growth in total kidney 
volume over a period of three years when using gold standard total kidney volume (mTKV) 
or estimated kidney volume using the ellipsoid method (eTKVELLIPSOID) or mid-slice method 
(eTKVPANK).
Supplementary Figure 1. Flow diagram of the study design and classification. We reviewed 
all available abdominal MRI-scan of patients with ADPKD who participated in the Otsuka 
284 single Center Study, TEMPO 3:4 study and DIPAK 1 Study from 2007 through 2014. 264 
patients were included of whom 44 were excluded, because not all views (coronal sagittal, 
transversal) were available. 193 patients were eligible for risk classification and 27 patients 
were excluded due to atypical cases of ADPKD. The classification was based on Irazabel et al.
mTKV eTKVELLIPSOID eTKVPANK
20% 417 274 332
30% 186 122 143
40% 105 69 81
50% 67 44 52
OTSUKA 284 Single  






All patients with MRI 
images
N=264
Patients with all  
views available
N=220
Patients eligible for risk 
classification 
N=193
Excluded: scans of 
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Supplementary Figure 2. Associations between measured left kidney volume (mKV) and 
repeated mKV (mKVREPEAT) (upper panels), estimated left kidney volume using ellipsoid 
method (eKVELLIPSOID) (middle panels) and using mid-slice method (eKVPANK) (lower panels). 
Left panel shows scatter plots (solid line representing the line of identity and the dotted 
line the actual regression line), whereas the right panel shows Bland-Altman plots (solid line 
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Supplementary Figure 3. Associations between measured right kidney volume (mKV) and 
right repeated mKV (mKVREPEAT) (upper panels), estimated right kidney volume using el-
lipsoid method (eKVELLIPSOID) (middle panels) and using mid-slice method (eKVPANK) (lower 
panels). Left panel shows scatter plots (solid line representing the line of identity and the 
dotted line the actual regression line), whereas the right panel shows Bland-Altman plots 
(solid line indicating no difference, and dotted lines representing mean difference [i.e. bias] 
and 95% confidence interval).
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